Oral calcitriol for reduction of proteinuria in patients with IgA nephropathy: a randomized controlled trial - PubMed (original) (raw)
Randomized Controlled Trial
doi: 10.1053/j.ajkd.2011.09.014. Epub 2011 Oct 22.
Affiliations
- PMID: 22019331
- DOI: 10.1053/j.ajkd.2011.09.014
Randomized Controlled Trial
Oral calcitriol for reduction of proteinuria in patients with IgA nephropathy: a randomized controlled trial
Li-Jun Liu et al. Am J Kidney Dis. 2012 Jan.
Abstract
Background: Vitamin D has shown efficacy in the reduction of proteinuria in patients with chronic kidney disease. This study aimed to determine the effect of calcitriol on urinary protein excretion in patients with immunoglobulin A (IgA) nephropathy.
Study design: Open-label, non-placebo-controlled, randomized study.
Setting & participants: 50 patients with IgA nephropathy were enrolled. The main criterion for inclusion was urinary protein excretion >0.8 g/d after renin-angiotensin system-inhibitor treatment for at least 3 months.
Intervention: Patients were randomly assigned (1:1) to receive 2 doses (0.5 μg) of calcitriol per week or no treatment for 48 weeks.
Outcomes: The primary end point was to compare change in 24-hour urinary protein excretion from baseline to last measurement during treatment.
Measurements: Every 8 weeks, there was measurement of 24-hour urinary protein excretion, serum calcium, serum phosphorus, serum creatinine, and intact parathyroid hormone.
Results: Measurement of the primary end point showed changes in urinary protein excretion of +21% (from 1.29 to 1.58 g/24 h; 95% CI, -9% to +52%) in the control group and -19% (from 1.60 to 1.30 g/24 h; 95% CI, -42% to +4%) in the calcitriol-treated group. There was a significant decrease in proteinuria in the calcitriol-treated group compared with the control group (difference between groups, 41%; 95% CI, 5%-79%; P = 0.03). The secondary end point of achieving at least a 15% decrease in proteinuria was attained by 7 of 24 (29%) controls and 17 of 26 (65%) of those treated with calcitriol (P = 0.02). No significant differences were observed in decrease in estimated glomerular filtration rate and change in blood pressure between the 2 groups. The incidence of recorded adverse events was similar between the 2 groups.
Limitations: Small and non-placebo-controlled study.
Conclusions: The addition of calcitriol to a renin-angiotensin system inhibitor resulted in a safe decrease in proteinuria in patients with IgA nephropathy.
Copyright © 2011 National Kidney Foundation, Inc. Published by Elsevier Inc. All rights reserved.
Similar articles
- Oral calcitriol for the treatment of persistent proteinuria in immunoglobulin A nephropathy: an uncontrolled trial.
Szeto CC, Chow KM, Kwan BC, Chung KY, Leung CB, Li PK. Szeto CC, et al. Am J Kidney Dis. 2008 May;51(5):724-31. doi: 10.1053/j.ajkd.2007.12.038. Epub 2008 Apr 3. Am J Kidney Dis. 2008. PMID: 18436082 Clinical Trial. - Oral paricalcitol in the treatment of patients with CKD and proteinuria: a randomized trial.
Fishbane S, Chittineni H, Packman M, Dutka P, Ali N, Durie N. Fishbane S, et al. Am J Kidney Dis. 2009 Oct;54(4):647-52. doi: 10.1053/j.ajkd.2009.04.036. Epub 2009 Jul 12. Am J Kidney Dis. 2009. PMID: 19596163 Clinical Trial. - An open label, randomized controlled study of oral calcitriol for the treatment of proteinuria in patients with diabetic kidney disease.
Krairittichai U, Mahannopkul R, Bunnag S. Krairittichai U, et al. J Med Assoc Thai. 2012 Mar;95 Suppl 3:S41-7. J Med Assoc Thai. 2012. PMID: 22619886 Clinical Trial. - Calcitriol in the treatment of IgA nephropathy with non-nephrotic range proteinuria: a meta-analysis of randomized controlled trials .
Deng J, Zheng X, Xie H, Chen L. Deng J, et al. Clin Nephrol. 2017 Jan;87 (2017)(1):21-27. doi: 10.5414/CN108915. Clin Nephrol. 2017. PMID: 27900938 Review. - Risk stratification of patients with IgA nephropathy.
Barbour SJ, Reich HN. Barbour SJ, et al. Am J Kidney Dis. 2012 Jun;59(6):865-73. doi: 10.1053/j.ajkd.2012.02.326. Epub 2012 Apr 11. Am J Kidney Dis. 2012. PMID: 22497792 Review.
Cited by
- IPNA clinical practice recommendations for the diagnosis and management of children with IgA nephropathy and IgA vasculitis nephritis.
Vivarelli M, Samuel S, Coppo R, Barratt J, Bonilla-Felix M, Haffner D, Gibson K, Haas M, Abdel-Hafez MA, Adragna M, Brogan P, Kim S, Liu I, Liu ZH, Mantan M, Shima Y, Shimuzu M, Shen Q, Trimarchi H, Hahn D, Hodson E, Pfister K, Alladin A, Boyer O, Nakanishi K; International Pediatric Nephrology Association. Vivarelli M, et al. Pediatr Nephrol. 2024 Sep 27. doi: 10.1007/s00467-024-06502-6. Online ahead of print. Pediatr Nephrol. 2024. PMID: 39331079 Review. - Non-immunosuppressive treatment for IgA nephropathy.
Tunnicliffe DJ, Reid S, Craig JC, Samuels JA, Molony DA, Strippoli GF. Tunnicliffe DJ, et al. Cochrane Database Syst Rev. 2024 Feb 1;2(2):CD003962. doi: 10.1002/14651858.CD003962.pub3. Cochrane Database Syst Rev. 2024. PMID: 38299639 - Anti-proteinuria effect of active vitamin D in patients with type 2 diabetic nephropathy.
Aref A, Khodhal M, Rashidi H, Farhangiyan Z, Bitaraf S. Aref A, et al. J Family Med Prim Care. 2022 Dec;11(12):7735-7742. doi: 10.4103/jfmpc.jfmpc_627_22. Epub 2023 Jan 17. J Family Med Prim Care. 2022. PMID: 36994046 Free PMC article. - Association of vitamin D status with disease severity and outcome in Indian patients with IgA nephropathy.
Farooqui N, Subbiah A, Chaturvedi P, Sati H, Singh G, Bhowmik D, Agarwal SK, Bagchi S. Farooqui N, et al. BMC Nephrol. 2023 Jan 17;24(1):15. doi: 10.1186/s12882-023-03061-0. BMC Nephrol. 2023. PMID: 36650464 Free PMC article. - The Role of Vitamin D in Kidney Transplantation Outcomes: A Systematic Review.
Koimtzis G, Stefanopoulos L, Brooker V, Geropoulos G, Chalklin CG, Gupta S, Carrington-Windo E, Papaioannou M, Papavramidis TS. Koimtzis G, et al. Life (Basel). 2022 Oct 20;12(10):1664. doi: 10.3390/life12101664. Life (Basel). 2022. PMID: 36295099 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Miscellaneous